Partnering Between Cancer Centers: The American College of Surgeons, National Cancer Institute, American Cancer Society, Centers of Disease Control, American Society of Clinical Oncology, Society of Surgical Oncology, American Society of Therapeutic Radiation and Oncology, and Association of Community Cancer Centers Are Needed to Stimulate Improved Clinical Cancer Care

2003 ◽  
Vol 21 (9) ◽  
pp. 1895-1895
Author(s):  
Robert W. Frelick
Keyword(s):  
Disease Control ◽  
Clinical Oncology ◽  
National Cancer Institute ◽  
Cancer Care ◽  
Surgical Oncology ◽  
Cancer Society ◽  
Cancer Centers ◽  
American College Of Surgeons ◽  
American Society ◽  
Therapeutic Radiation

scholarly journals Sentinel Lymph Node Biopsy for Melanoma: American Society of Clinical Oncology and Society of Surgical Oncology Joint Clinical Practice Guideline

2012 ◽  
Vol 30 (23) ◽  
pp. 2912-2918 ◽  
Author(s):  
Sandra L. Wong ◽  
Charles M. Balch ◽  
Patricia Hurley ◽  
Sanjiv S. Agarwala ◽  
Timothy J. Akhurst ◽  
...  
Keyword(s):  
Lymph Node ◽  
Sentinel Lymph Node ◽  
Disease Control ◽  
Clinical Oncology ◽  
Surgical Oncology ◽  
Breslow Thickness ◽  
Newly Diagnosed ◽  
Evidence Review ◽  
Regional Disease ◽  
American Society

Purpose The American Society of Clinical Oncology (ASCO) and Society of Surgical Oncology (SSO) sought to provide an evidence-based guideline on the use of lymphatic mapping and sentinel lymph node (SLN) biopsy in staging patients with newly diagnosed melanoma. Methods A comprehensive systematic review of the literature published from January 1990 through August 2011 was completed using MEDLINE and EMBASE. Abstracts from ASCO and SSO annual meetings were included in the evidence review. An Expert Panel was convened to review the evidence and develop guideline recommendations. Results Seventy-three studies met full eligibility criteria. The evidence review demonstrated that SLN biopsy is an acceptable method for lymph node staging of most patients with newly diagnosed melanoma. Recommendations SLN biopsy is recommended for patients with intermediate-thickness melanomas (Breslow thickness, 1 to 4 mm) of any anatomic site; use of SLN biopsy in this population provides accurate staging. Although there are few studies focusing on patients with thick melanomas (T4; Breslow thickness, > 4 mm), SLN biopsy may be recommended for staging purposes and to facilitate regional disease control. There is insufficient evidence to support routine SLN biopsy for patients with thin melanomas (T1; Breslow thickness, < 1 mm), although it may be considered in selected patients with high-risk features when staging benefits outweigh risks of the procedure. Completion lymph node dissection (CLND) is recommended for all patients with a positive SLN biopsy and achieves good regional disease control. Whether CLND after a positive SLN biopsy improves survival is the subject of the ongoing Multicenter Selective Lymphadenectomy Trial II. Copyright © 2012 American Society of Clinical Oncology and Society of Surgical Oncology. All rights reserved. No part of this document may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopy, recording, or any information storage and retrieval system, without written permission by the American Society of Clinical Oncology and Society of Surgical Oncology.

National Cancer Institute–American Society of Clinical Oncology Teams in Cancer Care Project

2016 ◽  
Vol 12 (11) ◽  
pp. 955-958 ◽  
Author(s):  
Michael P. Kosty ◽  
Amy Hanley ◽  
Veronica Chollette ◽  
Suanna S. Bruinooge ◽  
Steven H. Taplin
Keyword(s):  
Clinical Oncology ◽  
National Cancer Institute ◽  
Cancer Care ◽  
Care Project ◽  
American Society

scholarly journals Recomendaciones para cirugía en pacientes con patologías oncológicas durante la pandemia COVID-19

2020 ◽  
Vol 35 (2) ◽  
pp. 162-170 ◽  
Author(s):  
Maikel Adolfo Pacheco Trujillo ◽  
Pilar Adriana Torres Mesa ◽  
Fernando Arias Amezquita ◽  
Pinilla Morales Raúl Eduardo ◽  
Abadia Diaz Mario Arturo ◽  
...  
Keyword(s):  
National Comprehensive Cancer Network ◽  
Clinical Oncology ◽  
European Society ◽  
Surgical Oncology ◽  
American College Of Surgeons ◽  
American Society ◽  
Cancer Network

Para emitir las recomendaciones específicas frente a la población de pacientes con cáncer, se tomaron en cuenta diversas observaciones en pacientes con patologías oncológicas en momentos de COVID-19, que muestran riesgo mayor de complicaciones en esta población, así como las recomendaciones publicadas por las siguientes instituciones y asociaciones: National Comprehensive Cancer Network (NCCN), American College of Surgeons (ACS), American Society of Clinical Oncology (ASCO), European Society of Surgical Oncology (ESSO), Society of Surgical Oncology (SSO) y Asociación Española de Cirujanos (AEC). Si bien las recomendaciones sobre cuidado personal y prevención de COVID-19 para los pacientes con cáncer no difieren de las recomendaciones en la población general, es importante al momento de tomar decisiones relacionadas con su tratamiento, tener en cuenta todos los factores propios del entorno de cada paciente e institución, evaluando la situación epidemiológica de la zona, los recursos y talento humano disponibes para la atención, la condición particular y el entorno que rodea a cada paciente, con el fin de tomar la mejor decisión centrada en parámetros de bienestar y potencial control de la enfermedad.

scholarly journals Recomendaciones para el manejo de los pacientes quirúrgicos urgentes durante la pandemia covid-19

2020 ◽  
Vol 35 (2) ◽  
pp. 143-152 ◽  
Author(s):  
Liliana Cuevas-López ◽  
Juan Carlos Ayala Acosta ◽  
Orlando Alberto Velásquez-Jiménez ◽  
Jorge Alberto Navarro-Alean4 ◽  
Luis Gabriel González-Higuera ◽  
...  
Keyword(s):  
National Comprehensive Cancer Network ◽  
Clinical Oncology ◽  
European Society ◽  
Surgical Oncology ◽  
American College Of Surgeons ◽  
American Society ◽  
Cancer Network

Para emitir las recomendaciones específicas frente a la población de pacientes con cáncer, se tomaron en cuenta diversas observaciones en pacientes con patologías oncológicas en momentos de COVID-19, que muestran riesgo mayor de complicaciones en esta población, así como las recomendaciones publicadas por las siguientes instituciones y asociaciones: National Comprehensive Cancer Network (NCCN), American College of Surgeons (ACS), American Society of Clinical Oncology (ASCO), European Society of Surgical Oncology (ESSO), Society of Surgical Oncology (SSO) y Asociación Española de Cirujanos (AEC).

Clinical Oncology Practice 2015: Preparing for the Future

2015 ◽  
pp. e622-e627 ◽  
Author(s):  
Michael P. Kosty ◽  
Anupama Kurup Acheson ◽  
Eric D. Tetzlaff
Keyword(s):  
Clinical Oncology ◽  
Nurse Practitioners ◽  
Cancer Care ◽  
Medical Knowledge ◽  
Physician Assistants ◽  
The United States ◽  
Practice Model ◽  
American Society ◽  
Oncology Practice

The clinical practice of oncology has become increasingly complex. An explosion of medical knowledge, increased demands on provider time, and involved patients have changed the way many oncologists practice. What was an acceptable practice model in the past may now be relatively inefficient. This review covers three areas that address these changes. The American Society of Clinical Oncology (ASCO) National Oncology Census defines who the U.S. oncology community is, and their perceptions of how practice patterns may be changing. The National Cancer Institute (NCI)-ASCO Teams in Cancer Care Project explores how best to employ team science to improve the efficiency and quality of cancer care in the United States. Finally, how physician assistants (PAs) and nurse practitioners (NPs) might be best integrated into team-based care in oncology and the barriers to integration are reviewed.

Sign in / Sign up

Export Citation Format

Share Document